Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF2 | P09038 | 1/20 | 0.31 |
| ▸ | MDK | P21741 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975347 | 0.91 | NT5E (0.34) | FGF2MDKPDPK1MTORNT5E | |
| SCHEMBL15654703 | 0.86 | FGF2 (0.39) | FGF2MDKNT5E | |
| SCHEMBL13129896 | 0.86 | FGF2 (0.35) | FGF2MDKNT5E | |
| SCHEMBL15975393 | 0.86 | FGF2 (0.35) | FGF2MDKNT5E | |
| SCHEMBL1491955 | 0.83 | PDPK1 (0.36) | FGF2MDKPDPK1MTOR | |
| SCHEMBL1491923 | 0.82 | FGF2 (0.43) | FGF2MDKPDPK1MTOR | |
| SCHEMBL1973777 | 0.81 | NT5E (0.36) | FGF2PDPK1MTORNT5E | |
| SCHEMBL1034819 | 0.81 | NT5E (0.37) | PDPK1MTORNT5E | |
| SCHEMBL12757246 | 0.81 | NT5E (0.37) | PDPK1MTORNT5E | |
| SCHEMBL22423316 | 0.81 | NT5E (0.37) | PDPK1MTORNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7901687-B2 | Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections | ETH ZURICH (CH) | 2011-03-08 | — | — | US | disclosed |
| US-20090155299-A1 | Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections | SCHWEIZERISCHES TROPENINSTITUT (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155299-A1 | Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections | ANTXR2, CERT1, DAD1 | FGF2 2980/4885MDK 3902/4885PDPK1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.